HER2 targeted therapies market seen reaching $16.34 billion by 2030

The Business Research Company says the HER2 targeted therapies market is set to grow from $11.75 billion in 2026 to $16.34 billion by 2030, driven by personalized medicine, biomarker testing and next-generation drug formats. North America led the market in 2025, while Asia-Pacific is projected to grow fastest.

Why it matters: - HER2 targeted therapies are a major part of precision oncology for HER2-positive cancers, where treatment is designed to better match tumor biology and limit damage to healthy tissue. - The projected growth signals continued demand for targeted cancer drugs, biomarker testing and biologic manufacturing capacity. - The market outlook also points to more use of antibody-drug conjugates, biosimilars and combination regimens.

What happened: - The Business Research Company projected the HER2 targeted therapies market will rise from $11.75 billion in 2026 to $16.34 billion by 2030. - The forecast implies an 8.6% compound annual growth rate through 2030. - The company said the market reached $10.84 billion in 2025 and is on track for $11.75 billion in 2026, reflecting an 8.4% CAGR in the historical period described in the report. - North America held the largest market share in 2025. - Asia-Pacific is expected to be the fastest-growing region during the forecast period.

The details: - HER2 targeted therapies work by blocking the human epidermal growth factor receptor 2, a protein that can drive tumor growth. - The therapies either bind to the HER2 receptor or disrupt its signaling to slow cancer cell proliferation. - The report links market growth to rising breast and gastric cancer incidence, broader use of monoclonal antibodies such as trastuzumab, expanding oncology infrastructure in hospitals and higher clinical trial activity in HER2-positive cancers. - The forecast period is supported by rising adoption of precision oncology and biomarker testing. - The report points to progress in next-generation antibody-drug conjugates, more personalized cancer care, higher biotechnology and biologics investment and ongoing regulatory approvals for targeted oncology drugs. - Expected trends include wider ADC use in HER2-positive cancers, more biosimilar HER2 therapies, more chemotherapy and immunotherapy combinations, advances in next-generation tyrosine kinase inhibitors and more biomarker-guided treatment pathways. - The report covers Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, the Middle East and Africa. - The Business Research Company said its 2026 market reports include market attractiveness scoring, total addressable market analysis, company scoring matrix graphics and tables, Excel forecasting dashboards, market hotspots infographics, and updated graphics and tables. - The company also said the reports include key technologies and future trend analysis.

Between the lines: - Personalized medicine is doing more than supporting HER2 drug demand; it is reshaping how cancer care is selected, tested and delivered. - The FDA approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022, according to the Personalized Medicine Coalition in February 2024. - That approval trend suggests regulators and clinicians are increasingly comfortable with individualized therapies, which may help sustain adoption of HER2-targeted treatments. - The regional split suggests mature demand in North America and faster expansion potential in markets where cancer diagnostics and targeted therapy access are still scaling.

What's next: - The market’s next phase will likely depend on how quickly precision oncology, biomarker testing and ADC pipelines translate into routine cancer care. - Regulatory approvals for new targeted oncology drugs and broader use of combination regimens could add momentum through 2030. - Expansion in biologics manufacturing and biosimilar adoption may also reshape competition and pricing.

The bottom line: - HER2 targeted therapies are moving from a strong niche into a broader growth category in oncology, with the market forecast to add more than $4.5 billion by 2030.